Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.

Date publication

juin 2023

Journal

European urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique

Tous les auteurs :
Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37277275

Résumé

Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other DNA damage repair (DDR) gene alteration.

Mots clés

DNA damage repair gene alteration, Metastatic castration-resistant prostate cancer, Poly(ADP-ribose) polymerase inhibitor

Référence

Eur Urol. 2023 06 3;: